Serum concentration of co-trimoxazole during a high-dosage regimen

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 757-760

  Ameen, Sirwan Muhammed ^a   Rolain, Jean Marc ^a   Le Poullain, Marie Noelle ^a   Roux, Véronique ^a   Raoult, Didier ^a   Drancourt, Michel ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

MRSA; Sulfamethoxazole; Trimethoprim

Indexed keywords

ANTIINFECTIVE AGENT; COTRIMOXAZOLE;

CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ORAL DRUG ADMINISTRATION; SERUM;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; SERUM; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84887456838     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt400     Document Type: Article

References (20)

1. Huovinen P. Trimethoprim resistance. Antimicrob Agents Chemother 1987; 31: 1451-6.
2. Lode H. Co-trimoxazole from the therapeutic viewpoint. Infection 1987; 15 Suppl 5: S222-6.
3. Amini H, Ahmadiani A. Rapid and simultaneous determination of sulfamethoxazole and trimethoprimin human plasma by high-performance liquid chromatography. J Pharm Biomed Anal 2007; 43: 1146-50.
4. Gochin R, Kanfer I, Haigh JM. Simultaneous determination of trimethoprim, sulphamethoxazole and N4-acetylsulphamethoxazole in serum and urine by high-performance liquid chromatography. J Chromatogr 1981; 223: 139-45.
5. Spreux-Varoquaux O, Chapalain JP, Cordonnier P et al. Determination of trimethoprim, sulphamethoxazole and its N4-acetyl metabolite in biological fluids by high-performance liquid chromatography. J Chromatogr 1983; 274: 187-99.
6. Hof H. Pneumocystis jirovecii: a peculiar fungus posing particular problems for therapy and prophylaxis. Mycoses 2012; 55: 1-7.
7. Stein A, Bataille JF, Drancourt M et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with highdose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42: 3086-91.
8. Harmita, Mansur U, Sartika J. Optimation and validation of analytical method of co-trimoxazole in tablet and plasma in vitro by high performance liquid chromatography. J Bioanal Biomed 2012; 4: 026-9.
9. Bedor DC, Gonçalves TM, FerreiraML et al. Simultaneous determination of sulfamethoxazoleandtrimethoprimin biological fluids for high-throughput analysis: comparison of HPLC with ultraviolet and tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 863: 46-54.
10. Nakashima K, Ikeda R,Wada M. Analytical studies on the development of high-performance liquid chromatographicmethods with fluorescence or chemiluminescence detections and their practical applications. Anal Sci 2009; 25: 21-31.
11. Fass RJ, Prior RB, Perkins RL. Pharmacokinetics and tolerance of a single twelve-tabletdose of trimethoprim(960 mg)-sulfamethoxazole (4,800 mg). Antimicrob Agents Chemother 1977; 12: 102-6.
12. Reeves DS, Wilkinson PJ. The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues. Infection 1979; 7 Suppl 4: S330-41.
13. JoosB, Blaser J, OpravilMet al. Monitoringof co-trimoxazoleconcentrations in serum during treatment of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1995; 39: 2661-6.
14. Lambertus MW, Kwok RY, Mulligan ME. In vitro susceptibilities of oxacillin-resistant Staphylococcus aureus to dapsone and sulfamethoxazole alone and in combination with trimethoprim. Antimicrob Agents Chemother 1990; 34: 1453-5.
15. Schito GC, Debbia EA, Pesce A. Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: results of a collaborative surveillance study (1992-1993). J Antimicrob Chemother 1996; 38 Suppl A: 97-106.
16. Van Griethuysen A, Van 't Veen A, Buiting A et al. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J ClinMicrobiol 2003; 41: 2487-91.
17. Wisell KT, Kahlmeter G, Giske CG. Trimethoprim and enterococci in urinary tract infections: new perspectives on an old issue. J Antimicrob Chemother 2008; 62: 35-40.
18. Blaser J, Joos B, Opravil M et al. Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy. Infection 1993; 21: 206-9.
19. Kaplan SA, Weinfeld RE, Abruzzo CW et al. Pharmacokinetic profile of trimethoprim-sulfamethoxazole inman. J InfectDis1973; 128Suppl: S547-66.
20. Dudley MN, Levitz RE, Quintiliani R et al. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob Agents Chemother 1984; 26: 811-4.